Solid Biosciences LLC Net Assets
Solid Biosciences LLC net assets. Based on the latest financial reports, Solid Biosciences LLC (SLDB) has net assets worth $374.07 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($420.58 Million) and total liabilities ($46.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Solid Biosciences LLC to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $374.07 Million |
| % of Total Assets | 88.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -13.54% |
| 10-Year Change | N/A |
| Growth Volatility | 38.57 |
Net Assets of Solid Biosciences LLC (2015–2025)
Net assets of Solid Biosciences LLC from 2015 to 2025. This chart illustrates how Solid Biosciences LLC's net assets have evolved over time, based on quarterly financial data. See Solid Biosciences LLC (SLDB) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Solid Biosciences LLC (2015–2025)
The table below shows the annual net assets of Solid Biosciences LLC from 2015 to 2025. For live market cap and overall valuation, see SLDB stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $180.01 Million | +31.16% |
| 2024-12-31 | $137.25 Million | +8.51% |
| 2023-12-31 | $126.48 Million | -40.25% |
| 2022-12-31 | $211.67 Million | +1.66% |
| 2021-12-31 | $208.21 Million | +57.63% |
| 2020-12-31 | $132.09 Million | +65.01% |
| 2019-12-31 | $80.05 Million | -36.06% |
| 2018-12-31 | $125.18 Million | +311.25% |
| 2017-12-31 | $-59.26 Million | -56.41% |
| 2016-12-31 | $-37.89 Million | -90.14% |
| 2015-12-31 | $-19.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Solid Biosciences LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 89006400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Solid Biosciences LLC Net Assets Breakdown (December 2025)
Solid Biosciences LLC net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.00K | 0.04% |
| Other Comprehensive Income | $52.00K | 0.03% |
| Other Components | $1.14 Billion | 631.99% |
| Total Equity | $180.01 Million | 100.00% |
Solid Biosciences LLC Competitors by Market Cap
The table below lists competitors of Solid Biosciences LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
$673.42 Million |
|
Sunyard System Engineering Co Ltd
SHG:600571
|
$673.50 Million |
|
Zhejiang Truelove Vogue Co Ltd
SHE:003041
|
$673.66 Million |
|
Tianjin Economic-technological Development Area Co Ltd
SHE:000652
|
$673.68 Million |
|
Reitir fasteignafélag hf
IC:REITIR
|
$673.08 Million |
|
Cognyte Software Ltd
NASDAQ:CGNT
|
$672.93 Million |
|
Shanghai Smith Adhesive New
SHG:603683
|
$672.83 Million |
|
Henan Hengxing Science & Technology Co Ltd
SHE:002132
|
$672.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Solid Biosciences LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 137,246,000 to 180,010,000, a change of 42,764,000 (31.2%).
- Net loss of 174,325,000 reduced equity.
- Share repurchases of 1,681,000 reduced equity.
- New share issuances of 196,419,000 increased equity.
- Other comprehensive income increased equity by 5,000.
- Other factors increased equity by 22,346,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-174.32 Million | -96.84% |
| Share Repurchases | $1.68 Million | -0.93% |
| Share Issuances | $196.42 Million | +109.12% |
| Other Comprehensive Income | $5.00K | +0.0% |
| Other Changes | $22.35 Million | +12.41% |
| Total Change | $- | 31.16% |
Book Value vs Market Value Analysis
This analysis compares Solid Biosciences LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-52.66 | $6.28 | x |
| 2016-12-31 | $-65.80 | $6.28 | x |
| 2017-12-31 | $-27.57 | $6.28 | x |
| 2018-12-31 | $56.44 | $6.28 | x |
| 2019-12-31 | $29.80 | $6.28 | x |
| 2020-12-31 | $38.15 | $6.28 | x |
| 2021-12-31 | $29.25 | $6.28 | x |
| 2022-12-31 | $24.87 | $6.28 | x |
| 2023-12-31 | $6.36 | $6.28 | x |
| 2024-12-31 | $3.36 | $6.28 | x |
| 2025-12-31 | $2.06 | $6.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Solid Biosciences LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -96.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.29x
- Recent ROE (-96.84%) is below the historical average (-55.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $374.30K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.10 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.19 Million |
| 2018 | -59.75% | 0.00% | 0.00x | 1.12x | $-87.32 Million |
| 2019 | -146.44% | 0.00% | 0.00x | 1.29x | $-125.23 Million |
| 2020 | -66.84% | -2647.38% | 0.02x | 1.30x | $-101.50 Million |
| 2021 | -34.67% | -530.01% | 0.06x | 1.12x | $-93.01 Million |
| 2022 | -40.62% | -1062.28% | 0.03x | 1.23x | $-107.15 Million |
| 2023 | -75.91% | 0.00% | 0.00x | 1.30x | $-108.66 Million |
| 2024 | -90.86% | 0.00% | 0.00x | 1.37x | $-138.42 Million |
| 2025 | -96.84% | 0.00% | 0.00x | 1.29x | $-192.33 Million |
Industry Comparison
This section compares Solid Biosciences LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Solid Biosciences LLC (SLDB) | $374.07 Million | 0.00% | 0.12x | $673.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more